A recent study published in JAMA Network Open found that weight-loss drugs known as GLP-1 agonists may reduce the risk of obesity-related cancers compared to insulin treatment. The study analyzed data from over 1.6 million people with type 2 diabetes and found that those treated with GLP-1 drugs were less likely to be diagnosed with ten out of 13 obesity-related cancers. However, the study did not prove a definitive cause-and-effect relationship between the drugs and cancer risk reduction, and more research is needed. Additionally, newer GLP-1 drugs like Ozempic and Wegovy were not widely used during the study period.
Source link
Weight-loss jabs linked to lower cancer risk compared with insulin—new study
